INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
MHRAs cavalier attitude toward patient safety carries on apace

MHRAs cavalier attitude toward patient safety carries on apace

Anything goes for gene therapies, apparently, and your government doesn't care!

Hedley Rees's avatar
Hedley Rees
Aug 08, 2022
∙ Paid
13

Share this post

INSIDE PHARMA
INSIDE PHARMA
MHRAs cavalier attitude toward patient safety carries on apace
9
Share

MHRA updates its definition of reconstitution activities in 2022

In UK, MHRA has changed Regulations to facilitate mRNA technology (gene therapy), by changing its definition of reconstitution.

In the 2022 update to MHRAs Regulatory Bible, the Orange Guide, changes have been introduced to the rules that apply to Advanced Therapy Medicinal Products only (ATMPs – this includes gene therapies).

Section 16.12 of the 2022 Guide states:

“The following are examples of reconstitution activities relevant for ATMPs. It is stressed that these examples cannot be extrapolated to medicinal products other than ATMPs.

  • Thawing, washing, buffer exchange, centrifugation steps ready to remove preservation solution (eg dimethyl sulphoxide [DMSO]), removal of process related impurities (residual amount of preservation solution, dead cells), including filtering;

  • (Re)suspension, dissolution, or dilution with solvent/buffer, dispersion;

  • Mixing the product with patients own cells, with an adjuvant and/or with other s…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share